It seems that in both diabetic and non-diabetic postmenopausal women unopposed oestradiol replacement therapy is followed by an improvement in glucose homeostasis and a slight improvement or a neutral effect on insulin sensitivity. When progestogens are added, the beneficial oestrogen-induced effect on glucose metabolism is impaired or at least neutralised (partly dependent on the choice of progestogen). This also applies to the oestrogen effect on insulin sensitivity. An ideal progestogen should not abolish the positive effects on glucose metabolism by oestrogens and simultaneously decrease triglyceride levels in women with type 2 diabetes.
. PurdieDW. Consequences of long-term hormone replacement therapy. Br Med Bull2000; 56: 809–823.
2.
. PickarJHThorneycroftIWhiteheadM.Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol1998; 178: 1087–1099.
3.
. GrodsteinFGStampferMJMansonJAE. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med1996; 335: 453–461.
4.
. HulleySGradyDBushTFurbergCHerringtonDRiggsBVittinghoffE; for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998; 280: 605–613.
5.
. MansonJEColditzGAStampferMJ. A prospective study of maturity-onset diabetes and and risk of coronary heart disease and stroke in women. Arch Intern Med1991; 151: 1141–1147.
6.
. BiermanEL. Atherogenesis in diabetes. Arterioscler Thromb1992; 12: 647–656.
7.
. KaplanRCHeckbertSRWeissNS. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care1998; 21: 1117–1121.
8.
. AnderssonBMarinPLissnerLVermeulenABjorntorpP.Testosterone concentrations in women and men with NIDDM. Diabetes Care1994; 17: 405–411.
9.
. LindstedtGLundbergP-ALapidusL. Low sex-hormone-binding-globulin concentration as independent risk factor for development of NIDDM. Diabetes1991; 40: 123–128.
10.
. HaffnerSMValdezRAMoralesPAHazudaHPSternMP. Decreased sex-hormone-binding globulin predicts non-insulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab1993; 77: 56–60.
11.
. BjorntorpP.The android women - a risky condition. J Int Med1996; 239: 105–110.
12.
. GodslandIF. The influence of female sex steroids on glucose metabolism and insulin action. J Int Med1996; 240(Suppl 738): 3–60.
13.
. NabulsiAAFolsomARWhiteA. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med1993; 328: 1069–1075.
14.
. Barrett-ConnorELaaksoM.Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis1990; 10: 531–534.
15.
. MansonJARimmEBColditzGA. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin dependent diabetes mellitus. Ann Epidermiol1992; 2: 665–673.
16.
. BurkeC.Biologically active cortisol in plasma of oestrogen-treated and normal subjects. BMJ1969; 2: 798–800.
17.
. RinconJHolmangAWahlstromEO. Mechanisms behind insulin resistance in rat skeletal muscle following oophorectomy and additional testosterone treatment. Diabetes1996; 45: 615–621.
18.
. KumagaiSHolmangABjorntorpP.The effects of oestrogen and progesterone on insulin sensitivity in female rats. Acta Physiol Scand1993; 149: 91–97.
19.
. BrussaardHELeuvenJAFrolichMKluftCKransHMJ. Short-term estrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia1997; 40: 843–849.
20.
. KahnSELeonettiDLBoykoEJNewellILFujimotoWY. Insulin replacement therapy is associated with a reduction in disproportionate proinsulinemia in postmenopausal Japanese-American women. Diabetes1998; 47: A156.
21.
. CrookDGodslandIFHullJHStevensonJC. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet and Gynecol1997; 104: 298–304.
22.
. AnderssonBMattssonL-AHahnL. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab1997; 82: 638–643.
23.
. LuotolaHPyoralaTLoikkanenM.Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. Maturitas1986; 8: 245–253.
24.
. OwensDCollinsPBJohnsonATomkinGH. Lipoproteins and low-dose estradiol replacement therapy in post-menopausal type 2 diabetic patients: the effect of addition of norethisterone acetate. Diabetic Medicine2000; 17: 308–315.
25.
. SamarasKHaywardCSSullivanDKellyRPCampbellLV. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes. Diabetes Care1999; 22: 1401–1407.
26.
. ManwaringPMorfisLDiamondTHowesLG. The effects of hormone replacement therapy on plasma lipids in type II diabetes. Maturitas2000; 34: 239–247.
27.
. Mosnier-PudarHFaguerBGuyenneTTTchobroutskyG.Effects of deprivation and replacement by percutaneous 17β-oestradiol and oral progesterone on blood pressure and metabolic parameters in menopause patients with non-insulin-dependent diabetes. Arch Mal Coeur Vaiss1991; 84: 1111–1115.
28.
. AnderssonBMattssonL-A.The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in postmenopausal women with NIDDM. Acta Obstet Gynecol Scand1999; 78: 260–261.
